Compare Amcor PLC (AMCR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Sanofi SA — how do they compare? Amcor PLC trades at $43.01 (market cap $19.96B), while Sanofi SA trades at $43.71 (market cap $103.90B). The key difference: Sanofi SA is far larger — about 5.2× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| AMCR | SNY | |
|---|---|---|
Market Cap | $19.96B | $103.90B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $52.34 |
52-Week Low | $36.69 | $41.33 |
Enterprise Value | $35.08B | $120.39B |
Dividend Yield | 6.02% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
SNY trades at $43.50, down 0.91% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.10 vs. $1.06 expected, and maintains robust profitability with 71.92% gross margin and 15.95% net margin. Recent FDA approval for Sarclisa's subcutaneous formulation provides growth catalyst.
SNY presents a compelling investment case with solid earnings performance and pipeline advancements, though regulatory scrutiny in Europe and patent expiration risks for key drug Dupixent in 2031 warrant monitoring. Analyst consensus leans positive with 44% buy ratings, supporting a constructive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
